XERS / Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q4 2021 Results - Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ:XERS) revealed significant strides in its financial performance and collaboration agreements. The pharmaceutical comp more_horizontal

Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The c more_horizontal

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increa more_horizontal

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, K more_horizontal

Xeris Biopharma said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in a more_horizontal

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that the first participant has been dosed in a multi-center, open-label, Phase 2 study of XP-81 more_horizontal

Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment more_horizontal

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice P more_horizontal